MTH-68/N GETS SOME RESPECT
JNCI LAUDS NEWCASTLE TREATMENT;
HUNGARIANS TO ALLOW WIDESCALE USE

From The Cancer Chronicles #23
© Sept. 1994 by Ralph W. Moss, Ph.D.

A chicken farmer, who happens to have metastasized stomach cancer, suddenly and miraculously undergoes a complete and lasting disappearance of his tumor. Spontaneous remission? It turns out that just at that time, the man's flock was being devastated by an infectious disease of fowl called Newcastle Disease. The man had contracted a minor infection with Newcastle Disease Virus (NDV). The result of this inconsequential infection was a complete recovery from advanced cancer.

This case was published in Lancet in 1971 by a Hungarian-American scientist named Laszlo Csatary, MD (Lancet 1971;2:825). For nearly three decades, Csatary has been doggedly pursuing his vision of a treatment for cancer that is based on an attenuated, nonpathogenic form of the Newcastle Disease virus. (The worst side effect of NDV in some people is conjunctivitis or pink eye.) The result of his quest has been MTH-68/N, a vaccine made from a weakened strain of the Newcastle disease virus that cured that chicken farmer long ago.

Although Csatary has published in prestigious medical publications, often his papers have been rejected as irrelevant to the current fashions in cancer research. Through his publications and case histories, however, one can conclude that this inexpensive vaccine is sometimes quite effective against not just cancer, but against herpes and hepatitis B infections as well.

NOT MADE IN USA

The treatment could hardly be simpler; it is taken in the form of a nasal spray. In a Phase II multi-center trial in Budapest, it was recently shown to cause partial or complete tumor regression in eight out of 32 advanced patients (Cancer Detection and Prevention 1993;17:619-627) and symptomatic relief to many others. But although it is non-toxic and relatively inexpensive, and was developed in the US, Americans cannot get it here. Csatary no longer administers the treatment in the US for fear of FDA's reaction.

This summer there have been several promising developments in the MTH-68 story.

On June 21, [1994] there was a large media conference on MTH-68/N at the Hungarian Academy of Sciences, overlooking the Danube. This event was attended by about 150 persons, including many grateful patients. Also present, in addition to Laszlo Csatary and his wife Eva, was Sandor Eckhardt, MD, president of the International Union Against Cancer, and one of the leading cancer researchers in Europe. It was he who supervised the

latest clinical trial. After this conference, it was announced that the newly elected Hungarian government will now allow an unlimited number of patients to be enrolled in the current Phase II trial.

In addition, in the 8/17/94 edition of the Journal of the National Cancer Institute, there is a report on a similar treatment by Robert M. Lorence and colleagues at the Rush Presbyterian-St. Luke's Medical Center in Chicago. They announced the "complete regression of human neuroblastoma" in animals using NDV.

Although a rare cancer, neuroblastoma is the most common extra-cranial solid tumor in children. When this type of human cancer cell was transplanted into 11 "nude mice," a kind of rodent bred to accept human tumor grafts, they grew quickly. However, when a strain of NDV was injected directly into these lesions, "it caused all 11 tumors to regress completely (no palpable or visible tumor remained)," while rapid tumor growth continued in the control animals. The NDV-treated mice were then observed for 12 months, during which time, the Chicago scientists say, only one tumor reappeared. "A second virus treatment on day 23 led to complete regression of this tumor."

Lorence and his colleagues properly credit Dr. Laszlo Csatary for the initial work on NDV and also acknowledge that in the Budapest trial there were good results in about a quarter of the patients tested. There was also a lead editorial in JNCI about this exciting approach.


Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.



home - moss reports - books - - contact - order - news
members - chronicles - faq - free email newsletter